Promoter holding
64.27%
SB
Sequence Biotech Private Limited - Due diligence report
A 360° intelligence report on Sequence Biotech: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Sequence Biotech — 360° Intelligence Report
Generated from MCA filings & public records67/100
Trust Score
Moderate
Sequence Biotech is assessed as Moderate with a Trust Score of 67/100. Sequence Biotech is an active private limited indian non-government company incorporated in 2008, operating in the Agriculture sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.
Report generated on 27 Jun 2026 from the latest processed filings. Sequence Biotech Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
67/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
30/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 50/100 Moderate
- Negative operating earnings - debt service depends on external support.
- Profitable - internal accruals available.
Charges position: 3 open (6.02 cr) · 0 satisfied (-).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Bank Of Maharashtra | 1 | 48.0 cr |
| Others | 2 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 55/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RAJENDRA JAISING PATIL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUNITA NARENDRA AGHAV | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHRIRAM GANESH BHALERAO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHRIKANT SHANKAR BAPAT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIJAY MADHUSUDHAN BIBIKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- SHRIRAM GANESH BHALERAO has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2022 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Ambika Plast And Chem Private Limited | Associate Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 55
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Profit expanded 1.42 year-on-year.
Net margin improved to 2.1x.
EPFO headcount growing - hiring signal.
Operating for 17+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Negative net worth.
3 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence74/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment55/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 6.02 cr already registered.
- Compliance record supports lending.
Investor view59/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
21 Nov 2024
Charge created
Others - 20.35 Lakh
27 Sep 2024
Charge created
Others - 41.49 Lakh
07 Jun 2022
Director ceased
VIRENDRA SITARAM UPADHYE
30 Mar 2014
Securities allotted
673077.00 Equity Shares - 67.31 Lakh raised
09 Jun 2011
Charge created
Bank Of Maharashtra - 5.40 cr
10 Jan 2011
Securities allotted
1200000.00 Equity Shares - 1.20 cr raised
02 Dec 2010
Director appointed
SHRIRAM GANESH BHALERAO (Director)
Director appointed
SHRIKANT SHANKAR BAPAT (Director)
Director appointed
VIJAY MADHUSUDHAN BIBIKAR (Director)
Director ceased
ASHWINI GOKUL WAGH
Director ceased
ALKA RAJENDRA PATIL
30 Sep 2008
Securities allotted
50000.00 Equity Shares - 5.00 Lakh raised
19 Sep 2008
Incorporated
Registered with Roc Mumbai
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Dynamic Laboratories Pvt Ltd | U74899DL1979PTC009820 | Delhi, Delhi, India |
| Autocar Colour & Coatings Private Limited | U24100MH2013PTC247630 | Dombivli, Maharashtra, India |
| Max Colours And Chemicals Private Limited | U24114TG2001PTC036495 | Hyderabad, Telangana, India |
| Karsy Health Care Private Limited | U24232KA2002PTC031035 | Bangalore, Karnataka, India |
| Eagle Wings Healthcare Private Limited | U51909DL2020PTC366155 | Delhi, Delhi, India |
| Promoter'S Power Private Limited | U40108MP2009PTC022426 | Indore, Madhya Pradesh, India |
| Mangalore Puf Industries Private Limited | U24299KA2016PTC093168 | Mangalore, Karnataka, India |
| Risiga Agro (India) Private Limited | U24211MP2001PTC014842 | Indore, Madhya Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Sequence Biotech before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Sequence Biotech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 80/100, margin trends, ownership structure and peer set for Sequence Biotech - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 67/100, distress signals and MSME payment-delay disclosures - know whether Sequence Biotech pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Sequence Biotech - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Sequence Biotech an active company?
Sequence Biotech has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Sequence Biotech financially healthy?
Sequence Biotech has a Financial Health Score of 30/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Sequence Biotech?
Its overall Trust Score is 67/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Sequence Biotech?
Promoters hold the largest single block of equity - exact percentages are in the full report. 5 active director(s) are on record.
Does Sequence Biotech have loans or charges against its assets?
3 open charge(s) are registered against its assets.
Is Sequence Biotech up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Sequence Biotech?
Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
